



# CDDF MULTI - STAKEHOLDER WORKSHOP

## The Use of Real-World Data to Optimise Oncology Drug Development and Access

Amsterdam, Netherlands  
21-22 November 2019

### PROGRAMME



## EVENT OUTLINE

Due to the current interest in Real World Data both from Industry but especially the EMA and FDA, the Cancer Drug Development Forum organizes a multi-stakeholder workshop on the Use of Real-World Data to Optimise Oncology Drug Development and Access on 21-22 November, 2019 in Amsterdam, NL.

The aim of the workshop is to have a multi-stakeholder discussion representing regulators, clinicians, HTA / payers, and policy makers on the challenges of developing RWD proposals in oncology and share current experience on the best sources of RWD of high quality in oncology drug development.

The discussion will focus particularly on issues concerning methodology of collecting good quality and relevant information, and the specific requirement of regulators to maximise the use of RWD in licensing decisions. We will also explore possible solutions to the current challenges and collaboratively search for agreements.

## PROGRAMME COMMITTEE

- John Smyth (University of Edinburgh - CDDF Board, UK) - Programme Chair
- Nafsika Kronidou Horst (Roche, CH)
- Stefan Schwoch (Lilly, UK)
- Eva Skovlund (Norwegian University of Science and Technology, NO)

## TARGET AUDIENCE

The target is a multidisciplinary audience of patient associations, academia representatives, EU and US regulatory bodies (EMA, FDA & national agencies), pharmaceutical industry, and HTAs.

## WORKSHOP VENUE & HQ HOTEL

Room Mate Aitana Hotel

[www.room-matehotels.com/en/aitana/](http://www.room-matehotels.com/en/aitana/)

Address: IJDok 6 1013 MM - Amsterdam, Netherlands.

Phone: (+31) (0) 20 89 14 800

## MEETING SECRETARIAT

Cancer Drug Development Forum (CDDF)

c/o BLSI

Clos Chapelle-aux-Champs 30

1200 Brussels, Belgium

Tel: +32 2 880 62 70

Email: [info@cddf.org](mailto:info@cddf.org)

[www.cddf.org](http://www.cddf.org)

# PROGRAMME

## Day 1 Thursday 21 November 2019


MEETING ROOM: OSCAR

- 13:00 **Welcome Note**  
John Smyth (CDDF Board, UK)
- 13:15 **Overview of the Current RWD Landscape**  
Nafsika Kronidou Horst (Roche, CH)

### SESSION 1: THE CURRENT POSITION AND KEY CHALLENGES

**Session-chairs:** John Smyth (CDDF, UK) & Nafsika Kronidou Horst (Roche, CH)


#### Current Attitudes and Key Challenges : Regulators & Payers Perspective

- 13:30 **European Medicines Agency**  
Ralf Herold (EMA, NL)
- 13:50 **Health Technology Assessment**  
Carin Uyl-de Groot (Erasmus Universiteit Rotterdam, NL)
- 14:10  Q&A Session / Discussion (10')

#### Current Attitudes and Key Challenges : Clinician's Perspective & Industry Case Studies

- 14:20 **Clinician's Perspective on RWD Repositories**  
Jaap Verweij (Erasmus Universiteit Rotterdam/CDDF, NL)
- 14:40 **Industry Case Study 1: Real-World Comparator in a Single-Arm Study**  
Valérie André (Lilly, FR)
- 14:50 **Industry Case Study 2: A Pan-Cancer Registry Proposal**  
Marlene Thomas (Roche, CH)

#### Current Attitudes and Key Challenges : Patient Perspective

- 15:00 **Patient Perspective**  
Roger Wilson (UK)
- 15:10  Coffee Break (20')

## SESSION 2: METHODOLOGICAL ISSUES

**Session-chairs** : Eva Skovlund (Norwegian University of Science and Technology, NO)  
& Ralf Herold (European Medicines Agency, NL)

15:30 **Introduction to Methodological Challenges**  
Eva Skovlund (NTNU, NO)

### DATA COLLECTION

15:35 **Disease-Based Registries**  
Espen Enerly (Norwegian Cancer Registry, NO)

16:05 **Product-Based Registries**  
Elmar Schmitt (Merck Healthcare KGaA, DE)

16:30 **Wearables and Patient Reported Outcomes: New Wins?**  
Cécile Ollivier (Aparito, NL)

16:55  Q&A Session / Discussion (15')

### DATA ANALYSIS

17:10 **Statistical Considerations in Building External Control**  
Chris Harbron (Roche, UK)

17:35 **Electronic Healthcare Records**  
Meghna Samant (Flatiron Health, US)

18:00 **Introduction of Breakout Sessions (30')**

19:00  Welcome Drinks (private dining room at I-Dock restaurant, Room Mate)

19:30  Networking Dinner (private dining room at I-Dock restaurant, Room Mate)

## Day 2 Friday 22 November 2019


### SESSION 3: IDENTIFYING SOLUTIONS - BREAKOUT SESSIONS

09:00 **Identifying Solutions - 4 Breakout Sessions**  
Moderator: Gracy Crane (Roche, UK)  
*See the detailed information regarding the breakout sessions on the next page.*

11:00  **Coffee Break**

11:30 **Consolidating Outcomes from Breakout Sessions**

12:30 **Wrap-up and Next Steps**  
John Smyth (CDDF, UK)

13:00  Lunch (I-Dock restaurant, Room Mate)

# BREAKOUT SESSIONS

## SESSION 1 : REGULATORY AND HTA ENVIRONMENT FOR THE USE OF RWE

### Meeting room: Oscar (ground floor)

Chairs: Stefan Schwoch (Lilly, UK) & Larissa Higgins (Health Products Regulatory Authority, IL)

This breakout session will explore what the current environment is, look at enablers/ opportunities, barriers/uncertainties, examples/ case studies and possible solutions/ recommendations. We will discuss pre- and post-marketing and cover similarities and differences for the areas of regulatory review and HTA.

## SESSION 2 : PATIENT VOICE

### Meeting room: Valeria (ground floor)

Chairs: Roger Wilson (UK) & Irmela Radtke (Roche, CH)

With the aim of achieving better treatments, better information to support patients, and more meaningful outcomes, this session will explore and analyze possible solutions in the context of patient-centred research, pathway approach, funding and new challenges to be addressed.

## SESSION 3 : ENSURING ROBUST DECISION MAKING FROM THE ANALYSIS OF RWD

### Meeting room: Emma (1<sup>st</sup> floor)

Chairs: Chris Harbron (Roche, UK) & Eva Skovlund (NTNU, NO)

In this session, participants will discuss some of the key criteria that need to be in place in order to make robust decisions from RWD:

- In which settings could using RWD be most valuable?
- How can we avoid biases?
- When biases are unavoidable?
- How do obtain a realistic estimate of the uncertainty of any conclusions?
- How do we communicate our levels of confidence to internal and external stakeholders

## SESSION 4 : DATA COLLECTIONS SYSTEMS

### Meeting room: Isabella (1<sup>st</sup> floor)


Chairs: Meghna Samant (Flatiron, US) & Bjørg Bolstad (Norwegian Medicines Agency, NO)

This session will focus on real world data collection systems that exist today in Europe and US along with current and future uses of these data to facilitate regulatory and reimbursement decision making. Most importantly, the session will build upon key challenges identified and will propose solutions for the wider adoption of these data to accelerate drug development and patient access.

## MEETING ROOMS GROUND FLOOR MAP

**BREAKOUT SESSION 2**  
**VALERIA**  
Patient voice

**BREAKOUT SESSION 1**  
**OSCAR**  
Regulatory and HTA environ-  
ment for use of RWE



① ENTRANCE

④ STAIRS

② FRONT DESK

⑤ OSCAR MEETING ROOM **BREAKOUT SESSION 1**


③ ELEVATORS

⑥ VALERIA MEETING ROOM **BREAKOUT SESSION 2**

## MEETING ROOMS FIRST FLOOR MAP

**BREAKOUT SESSION 3**  
**EMMA**  
Ensuring robust decision making  
from the analysis of RWD

**BREAKOUT SESSION 4**  
**ISABELLA**  
Data collections systems



① ENTRANCE

④ STAIRS

⑦ CARLA MEETING ROOM

② FRONT DESK

⑤ GRACE MEETING ROOM

⑧ EMMA MEETING ROOM

③ ELEVATORS

⑥ ALICIA MEETING ROOM

**BREAKOUT SESSION 3**

⑨ ISABELLA MEETING ROOM

**BREAKOUT SESSION 4**





SPRING  
CONFERENCE  
2020

**JOIN OUR MULTI-STAKEHOLDER  
DISCUSSIONS TO ACCELERATE  
THE DELIVERY OF EFFECTIVE AGENTS  
TO PATIENTS!**

**10-12 FEBRUARY 2020  
NOORDWIJK AAN ZEE**

## **CDDF 11TH SPRING CONFERENCE 2020**

**CDDF Spring Conference 2020** is a unique forum that convenes every 18 months and gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, regulatory authority representatives as well as patient advocacy groups. It is the successor of the former CDDF Alpine Conference and the 11th edition takes place from 10 to 12 February 2020 in Noordwijk aan Zee, the Netherlands.

This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions and case studies along with networking opportunities.

### **Discussion Topics:**

- ✔ Combination Therapies
- ✔ Tumor Agnostic Drug Development
- ✔ Cell Therapies
- ✔ Revision of Anticancer Guidelines

### **Key Information:**

- ✔ Date: 10-12 February 2020
- ✔ Location: Noordwijk aan Zee, NL
- ✔ Venue: Radisson Blu Palace Hotel
- ✔ Registration: until January 27, 2020

***Stay Informed about the CDDF 11<sup>TH</sup> Spring Conference 2020!***

**→ [WWW.CDDF.ORG](http://WWW.CDDF.ORG)**

